Edwin Moses

Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK.

The Group's principal activity is the provision of technology solutions to the clinical trials industry. The Group's technology, services and products provide its customers, typically pharmaceutical and biotechnology companies, collects data and arrange clinical trials. These includes a range of consultancy, services and software. The Group's products includes ClinPhone Patient Recruitment, ClinPhone Randomisation, ClinPhone Trial Supply Management, ClinPhone ePRO, ClinPhone Clinical Trials Management Software, ClinPhone Drug Accountability, ClinPhone Integration Services and ClinPhone Trial Supply Simulation.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Fusion IP Ltd. operates as a holding company. It engages in the commercialization of intellectual properties that is developed at universities and similar establishments. The company was founded by Peter Leonard Grant, Stewart Gall and David Graham Baynes in 2002 and is headquartered in Sheffield, the United Kingdom.

Capricorn Partners NV (Capricorn) is an independent European licensed manager of private and public equity investment funds which was founded in 1993 as a joint venture between Dr Jos B. Peeters and Baring Venture Partners Ltd. In 1999, Capricorn became a fully partner-owned, independent firm. It is headquartered in Leuven, Belgium.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands

Ionix Pharmaceuticals Ltd. used to develop analgesic medicines for the treatment of acute and chronic pain. Its drugs were used for the treatment of pain associated with chronic debilitating diseases such as osteoarthritis, diabetes, cancer and multiple sclerosis. The company was founded by Andrew Sandham, Phillip J. Birch, John Wood and Ann Gail Hayes in 2001 and was located in Cambridge, UK.

Lectus Therapeutics Ltd. Developed ion channel modulators and therapeutics. The company was founded in December 2002 and was headquartered in Cambridge, the United Kingdom.

Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Capricorn Health-Tech Fund NV invests in companies located in Western Europe. It targets companies operating in the fields of human health-technology. It provides financing for seed stage, early stage and growth stage in equity and debt with an investment size between EUR 0.5 million and EUR 6 million. It acquires mostly minority stakes but also majority stakes.

Oxford Drug Design Ltd. develops application of new technologies to drive computer-aided drug discovery. It specializes in drug discovery, molecular modeling, lead identification and optimisation, formulation modeling and preclinical studies. The company was founded by W. Graham Richards in 2001 and is headquartered in Oxford, the United Kingdom.

The London Technology Network provides academic training in computer science, life science and physical science. It also offers technology consulting services to member companies. The company is headquartered in London, the United Kingdom.

Part of Evotec SE, ProPharma Ltd. engages in pharmaceutical research and manufactures clinical trial supplies. The company is based in Glasgow, UK. ProPharma was acquired by Evotec SE from University of Strathclyde on October 25, 2005.

Proimmune Ltd. develops, manufactures and distributes drugs. Its services include antigen characterization: T and B cell epitope discovery, immunogenicity risk management assays and cellular analysis services. The firm's products include pentamers, tetramers and monomers, CD1d tetramers, custom peptide products and antibodies. The company was founded by Linda Tan and Nikolai Schwabe in 2000 and is headquartered in Oxford, the United Kingdom.

Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom.

Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals.

Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom.

Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA.